A9613 HCPCS code: Piflufolastat f 18 (pylarify truvu), diagnostic, 1 millicurie
A9613 is the HCPCS Level II code for piflufolastat f 18 (pylarify truvu), diagnostic, 1 millicurie. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case.
Code details
| Field | Value |
|---|---|
| Section | A codes — Transportation, medical/surgical supplies and miscellaneous |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 57 |
| BETOS category | I1E |
| Added | 2026-10-01 |
| Last action effective | 2026-10-01 |
What changed for A9613
- October 2026: Code appears in this HCPCS release
- 2026-10-01: A9613 added to HCPCS Level II
- 2026-10-01: Last CMS action: code added
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code A9613?
A9613 is the HCPCS Level II code for piflufolastat f 18 (pylarify truvu), diagnostic, 1 millicurie. Short descriptor: "F 18 pylarify truvu, dx 1mci".
Does Medicare cover A9613?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related A96 codes
- A9600 — Strontium sr-89 chloride, therapeutic, per millicurie
- A9601 — Flortaucipir f 18 injection, diagnostic, 1 millicurie
- A9602 — Fluorodopa f-18, diagnostic, per millicurie
- A9603 — Injection, pafolacianine, 0.1 mg
- A9604 — Samarium sm-153 lexidronam, therapeutic, per treatment dose, up to 150 millicuries
- A9606 — Radium ra-223 dichloride, therapeutic, per microcurie
- A9607 — Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie
- A9608 — Flotufolastat f 18, diagnostic, 1 millicurie
- A9609 — Fludeoxyglucose f18 up to 15 millicuries
- A9610 — Xenon xe-129 hyperpolarized gas, diagnostic, per study dose
- A9611 — Flurpiridaz f 18, diagnostic, 1 millicurie
- A9612 — Injection, fluorescein, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under A9613
- Watch A9613 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for A9613
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.